Skip to main content
Plaque psoriasis drugs from AbbVie, Pfizer, Janssen recommended by NICE

A final guidance document has been issued by the National Institute for Health and Care Excellence recommending the 16-week use of AbbVie's Humira, or adalimumab, and Janssen's Stelara, or ustekinumab, as options for treating plaque psoriasis in children and young people whose disease is severe, who cannot use other treatments or who have not improved with the use of other treatments. NICE also backed the use of Pfizer's Enbrel, or etanercept, for 12 weeks for the same indication.

Full Story: